Research and Markets (http://www.researchandmarkets.com/research/gj92x9/india_coronary)
has announced the addition of the "India
Coronary Stent and Angioplasty Market Through 2020 (Cath Lab Level
Information - City, State and National)" report to their
offering.
The coronary stent market in India, which comprises
Drug Eluting Stent (DES), Bare Metal Stent (BMS) and Bio-Absorbable
Stent (BVS), was valued above $400 million in 2012. DES accounts for
bulk of sales in India. The bio-absorbable stent ABSORB has garnered a
considerable traction despite its high cost compared with the other
available DES.
The key players operating in the segment are
Alvimedica, Abbott Vascular, a division of Abbott Laboratories ABT, Boston Scientific (NYSE : BSX, LSE : BSX), Biosensors Inc.,
Biotronik, JW Medical, Medtronic, Inc. MDT, Meril Life Sciences,
MicroPort Scientific Corporation (HKG: 0853), Sahajanand Medical
Technologies and Translumina Therapeutics.
The market has
grown impressively supported by a rise in coronary angioplasties which
has resulted from a surge in cardiovascular diseases (CVDs), augmented
healthcare spending as well as an increase in number of interventional
cardiologists and cath labs in government and private hospitals,
including individual cath lab centres run by interventional
cardiologists as well as new corporate hospitals.
The demand
has surged as central and state governments capped reimbursement rates
which enhanced affordability resulting in an increase in volume. The
decrease in reimbursement rates has given an edge to Indian, Asian and
some of the Europe-based mid-sized MNCs which sell stents at almost half
the price of those sold by US companies.
In the US, the
stents market has slumped significantly due to negative results from
clinical studies suggesting that one-third of stent implants are
unnecessary. However, in India these studies have not made an impact as
most Indian cardiologists do not seem to have taken these clinical
outcomes seriously.
India Coronary Stent and Angioplasty
Market Through 2020 (Cath Lab Level Information - City, State and
National)', is a market report that reviews historical trends and
forecasts (between 2007 and 2020), annualised sales, market size (value
and units), market growth, pricing, competitive landscape and market
share.
The research report covers 700 cath labs across the
country. It analyses angioplasty procedures' (PCI and PTCA) data for the
country with a detailed analysis at national, state, district, city and
hospital levels. It provides PCI data of 550 hospitals from more than
150 cities.
Companies Mentioned
-
Abbott Vascular, a division of Abbott Laboratories
- Alvimedica
-
Biosensors Inc.
- Biotronik
- Boston Scientific
- JW
Medical
- Medtronic Inc.
- Meril Life Sciences
-
MicroPort Scientific Corporation
- Sahajanand Medical Technologies
-
Translumina Therapeutics
For more information visit http://www.researchandmarkets.com/research/gj92x9/india_coronary
View source version on businesswire.com: http://www.businesswire.com/news/home/20150724005356/en/
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector:
Cardiovascular
Devices, Stents
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.